Evidence map›Paper›PMID 38166711›Full record

ArticleBMC public health2024

Increasing the uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) through seasonal malaria chemoprevention channel delivery: protocol of a multicenter cluster randomized implementation trial in Mali and Burkina Faso.

Kadiatou Koita, Joel D Bognini, Efundem Agboraw, Mahamadou Dembélé, Seydou Yabré, Biébo Bihoun, Oumou Coulibaly, Hamidou Niangaly, Jean-Batiste N'Takpé, Maia Lesosky and 6 more

Open access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in BMC public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Kadiatou Koita *Department of Epidemiology of Parasitic Diseases (DEAP), Faculty of Medicine Odontostomatology, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali. kadiatou.koita@lstmed.ac.uk.
Joel D Bognini *Institut de Recherche en Sciences de La Santé (IRSS), Unité de Recherche Clinique de Nanoro, Ouagadougou, Burkina Faso.
Efundem AgborawLiverpool School of Tropical Medicine, Vector Biology, Liverpool, UK.
Mahamadou DembéléDepartment of Epidemiology of Parasitic Diseases (DEAP), Faculty of Medicine Odontostomatology, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali.
Seydou YabréInstitut de Recherche en Sciences de La Santé (IRSS), Unité de Recherche Clinique de Nanoro, Ouagadougou, Burkina Faso.
Biébo BihounInstitut de Recherche en Sciences de La Santé (IRSS), Unité de Recherche Clinique de Nanoro, Ouagadougou, Burkina Faso.
Oumou CoulibalyDepartment of Epidemiology of Parasitic Diseases (DEAP), Faculty of Medicine Odontostomatology, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali.
Hamidou NiangalyDépartement Etudes, Institut National de Santé Publique, Recherches Médicale Et Communautaire, Bamako, Mali.
Jean-Batiste N'TakpéUniversity of Bordeaux, National Institute for Health and Medical Research, Bordeaux, France.
Maia LesoskyDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Dario ScaramuzziR-Evolution Worldwide Srl Impresa Sociale (REvoWWIS), Naples, Italy.
Eve WorrallDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Jenny HillDepartment of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
Valérie BriandUniversity of Bordeaux, National Institute for Health and Medical Research (INSERM) UMR 1219, Research Institute for Sustainable Development (IRD) EMR 271, Bordeaux Population Health Centre, Bordeaux, France.
Halidou Tinto *Institut de Recherche en Sciences de La Santé (IRSS), Unité de Recherche Clinique de Nanoro, Ouagadougou, Burkina Faso.
Kassoum Kayentao *Department of Epidemiology of Parasitic Diseases (DEAP), Faculty of Medicine Odontostomatology, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali.
Liverpool School of Tropical Medicine · GBInstitut de Recherche en Sciences de la Santé · BFUniversité des Sciences, des Techniques et des Technologies de Bamako · MLUniversité de Bordeaux · FRInstitut National de Recherche en Santé Publique · ML

Funding

European and Developing Countries Clinical Trials Partnership RIA2020S-3302
6 · The paper itself

Abstract

backgroundThe uptake of Intermittent Preventive Treatment of malaria in pregnancy using Sulfadoxine-Pyrimethamine (IPTp-SP) remains unacceptably low, with more than two-thirds of pregnant women in sub-Saharan Africa still not accessing the three or more doses recommended by the World Health Organisation (WHO). In contrast, the coverage of Seasonal Malaria Chemoprevention (SMC), a more recent strategy recommended by the WHO for malaria prevention in children under five years living in Sahelian countries with seasonal transmission, including Mali and Burkina-Faso, is high (up to 90%). We hypothesized that IPTp-SP delivery to pregnant women through SMC alongside antenatal care (ANC) will increase IPTp-SP coverage, boost ANC attendance, and increase public health impact. This protocol describes the approach to assess acceptability, feasibility, effectiveness, and cost-effectiveness of the integrated strategy. METHODS AND ANALYSIS: This is a multicentre, cluster-randomized, implementation trial of IPTp-SP delivery through ANC + SMC vs ANC alone in 40 health facilities and their catchment populations (20 clusters per arm). The intervention will consist of monthly administration of IPTp-SP through four monthly rounds of SMC during the malaria transmission season (July to October), for two consecutive years. Effectiveness of the strategy to increase coverage of three or more doses of IPTp-SP (IPTp3 +) will be assessed using household surveys and ANC exit interviews. Statistical analysis of IPT3 + and four or more ANC uptake will use a generalized linear mixed model. Feasibility and acceptability will be assessed through in-depth interviews and focus group discussions with health workers, pregnant women, and women with a child < 12 months. DISCUSSION: This multicentre cluster randomized implementation trial powered to detect a 45% and 22% increase in IPTp-SP3 + uptake in Mali and Burkina-Faso, respectively, will generate evidence on the feasibility, acceptability, effectiveness, and cost-effectiveness of IPTp-SP delivered through the ANC + SMC channel. The intervention is designed to facilitate scalability and translation into policy by leveraging existing resources, while strengthening local capacities in research, health, and community institutions. Findings will inform the local national malaria control policies.

trial registrationRetrospectively registered on August 11th, 2022; registration # PACTR202208844472053. Protocol v4.0 dated September 04, 2023. Trail sponsor: University of Sciences Techniques and Technologies of Bamako (USTTB), Mali.

Indexed as

AntimalarialsMalariaPregnancy Complications, ParasiticBurkina FasoChemopreventionChildChild, PreschoolDrug CombinationsFemaleHumansMaliMulticenter Studies as TopicPregnancyPyrimethamineRandomized Controlled Trials as TopicSeasonsAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationPyrimethamineSulfadoxineEpidemiologyInfectious diseasesMalariaMaternal and child healthPregnant womenTropical medicineWomen with a child less than 12 months of age

Identifiers

PMID38166711
PMCPMC10763117
OpenAlexW4390508549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.